retatrutide powder Retatrutide | US Peptide Science

SURMOUNT-1 results (72 weeks, adults with obesity): 5 mg dose: approximately 15% body weight loss 10 mg dose: 19.5% body weight loss 15 mg dose: 22.5% body weight loss Placebo: 3.1% body weight loss At the 15 mg maximum dose, the average participant lost about 52 pounds over 72 weeks

[DOI] [PubMed] [Google Scholar] 219.Gao L., et al

The clinical data is clear: it does not

Whether GIP contributes 30% of the benefit or 50% matters less than the reality that adding it produces substantially better results

In the clinical trial of participants with type 2 diabetes, HbA1c reductions of -1.88% to -2.02% were observed at the 8 mg and 12 mg doses by 24 weeks

Data from the Centers for Disease Control and Prevention (CDC) in 2023 indicated that more than 37 million adults in the United States were living with diabetes, while obesity rates remained considerably high across the region